(4-6 months), and 61% had inactive disease at 12 months. The majority of patients improved, even if they did not achieve inactive disease. An improvement in the PVAS score of at least 50% from time of diagnosis to postinduction was seen in 92% of patients. Minor relapses occurred in 12 (24%) of 51 patients after inactive disease had been achieved postinduction. The median PVDI damage score at 12 months was 1 (range 0-6), and 63% of patients had ‡1 PVDI damage item scored as present at 12 months.
Conclusion. This is the largest study to date to assess disease outcomes in pediatric AAV. Although the study showed that a significant proportion of patients did not achieve remission, the majority of patients responded to treatment. Unfortunately, more than one-half of this patient cohort experienced damage to various organ systems early in their disease course.
Childhood antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is rare, and studies of disease outcomes in children are limited. The AAVs include granulomatosis with polyangiitis (Wegener's) (GPA), microscopic polyangiitis (MPA), eosinophilic granulomatosis with polyangiitis (ChurgStrauss) (EGPA), and localized disease variants such as pauci-immune necrotizing glomerulonephritis (GN). Although they occur rarely, these diseases are often organ-or life-threatening. Prior to the introduction of treatment with corticosteroids and cyclophosphamide, the disease was rapidly fatal in the majority of pediatric and adult cases (1) .
Evolving treatment strategies have significantly improved survival and reduced morbidity for patients with AAV. Due to the rarity of AAV in childhood, much of our knowledge about outcomes, such as remission, relapse, and damage, has come from studies in adult disease (2) (3) (4) (5) (6) (7) (8) (9) or small pediatric case series (2, (10) (11) (12) (13) (14) . Data from AAV studies in adults have shown remission rates as high as 90% (15) and 5-year survival rates of 80% (16) . Despite these advances, disease relapses occur in up to 30-50% of adult patients (17) (18) (19) . In addition, even when patients achieve remission, damage can be seen early in the disease course and tends to increase over time (4) . A recent retrospective study of 66 children with AAV from France assessed outcomes in children who had been followed up for a median of 5.2 years (20) ; 90% of the patients achieved remission after a median time of 6.7 months (interquartile range [IQR] 4.9-10.1), but 41% experienced at least 1 relapse after a median time of 29 months (IQR 14-89). To date, this French retrospective study has been the largest pediatric study of follow-up data for pediatric AAV, but because it was retrospective, remission or relapse rates at prespecified times were not reported.
A better understanding of remission rates, relapse rates, and other outcomes (ideally, using standardized pediatric-specific tools) will only be possible through international collaborations and use of international registries. Already, such initiatives have resulted in the development of pediatric-specific classification criteria (21) , formulation of the Pediatric Vasculitis Activity Score (PVAS) (22) , and ongoing initiatives to develop pediatric-specific vasculitis damage indices. The impact of disease (activity, severity, and damage) and its individual treatments (toxicity, safety, and efficacy) may be different in children, since their immune system is evolving, and comorbidities in children are likely to be different from those in adults. Moreover, the impact on physical and psychosocial growth and development is unique to children, and this requires long-term followup studies. For these reasons, research specific to pediatric patients is critically important.
The Pediatric Vasculitis Initiative (PedVas) is an international collaborative translational research initiative funded until 2017 by the Canadian Institutes of Health Research (for more details, see https://clinicaltrials.gov/ ct2/show/NCT02006134) with the primary aim of improving the lives of children with chronic vasculitis. Clinical data are being collected through 2 previously established web-based registries, ARChiVe (A Registry for Children with Vasculitis) for the study of chronic systemic vasculitis (see Supplementary Appendix A for a list of the sites and investigators in the ARChiVe network, available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.40112/ abstract) and BRAINWORKS, a registry for the study of primary angiitis of the central nervous system. The primary objective of the current study was to describe the early disease course of children with AAV. Specifically, the aims were 1) to describe the baseline clinical features of children with AAV, including organ involvement, disease activity, and treatments initiated, and 2) to characterize the early disease course and outcomes by determining treatment response (rates of remission, improvement, and inactive disease), relapse rates, and damage in the first 12 months of disease.
PATIENTS AND METHODS
Patients. The ARChiVe registry was established in March 2007 and initially collected data from the time of diagnosis only (23) , but since January 2013, with the support of PedVas, retrospective and prospective follow-up data have been collected. The current study is an inception cohort study using data from patients entered into the ARChiVe registry from 22 international sites.
Patient eligibility criteria, the registry data set, and the strategy for establishing the time of diagnosis data set have been described previously (23) . Eligible patients included were those who were diagnosed by the treating physician after January 1, 2004 and before the age of 18 years as having a primary chronic systemic vasculitis. Patient data were collected retrospectively for those diagnosed before March 2007, and prospectively for those diagnosed subsequently.
For the purpose of the present study, eligible subjects were children diagnosed before their eighteenth birthday as having GPA, MPA, EGPA, or ANCA-positive pauci-immune GN and who had complete follow-up data at postinduction (4-6 months after diagnosis) and at 12 months after diagnosis, collected through November 2015. Patients with a treating physician's diagnosis of ANCA-positive pauci-immune GN were included because, on further review, many of these children met the classification criteria for GPA or could be classified as having MPA after application of the European Medicines Agency (EMA) algorithm. Each eligible patient was reviewed and classified as follows. For EGPA, patients had to meet the American College of Rheumatology (ACR) criteria or the Lanham criteria for EGPA (24, 25) . For a diagnosis of GPA, patients had to meet the ACR criteria or the European League Against Rheumatism (EULAR)/Paediatric Rheumatology International Trials Organisation (PRINTO)/ Paediatric Rheumatology European Society (PRES) classification criteria for GPA (21, 24) . For MPA, because MPAspecific classification criteria are lacking, the diagnosis was formalized by applying a pediatric modification of the EMA algorithm for classifying AAV (incorporating the EULAR/ PRINTO/PRES classification criteria) (26) . Patients were excluded if they could not be classified as having GPA, MPA, or EGPA after application of the above-described criteria.
The ARChiVe registry uses a web-based interface for entry of data at several time points, including the time of diagnosis, postinduction (4-6 months after diagnosis), 12 months postdiagnosis, and flare visits. The study protocol was approved by the local research ethics board at each participating center. Informed consent for participation was obtained from parents, and informed consent or assent was obtained from patients for both retrospective and prospective recruitment. Study data were collected and managed using REDCap electronic data capture tools hosted at the University of British Columbia (27) .
Data collection. Categorical data collected included demographic data, treating physician's diagnosis, date of diagnosis, family and patient's medical history, presenting symptoms and interval history, clinical features, results of laboratory testing, diagnostic investigations, including diagnostic imaging or other procedures such as biopsies, medications, including the dosage of corticosteroid, the PVAS (maximum possible score of 63) (22) , and a modified version of the Vasculitis Damage Index (VDI) (28) for use in pediatrics (PVDI).
Outcome assessments. The primary outcome measure was achievement of disease remission at 12 months following diagnosis. Secondary outcome measures included rates of inactive disease at postinduction (4-6 months after diagnosis) and at 12 months after diagnosis, rates of improvement at postinduction and at 12 months, presence of damage at 12 months, and rates of relapse within 12 months. Definitions from the EULAR recommendations for conducting clinical studies in AAV (29) were used to define remission, improvement, relapse, and damage. In order to apply these definitions to pediatric data, the PVAS was used in place of the Birmingham Vasculitis Activity Score (BVAS) (30) , and the PVDI was used in place of the adult VDI (28) .
Remission was defined as a PVAS of 0 (inactive disease) and a dosage of prednisone (or equivalent) of ,0.2 mg/ kg/day. Adult guidelines recommend that remission should be defined as occurring only when a patient has attained a stable low dosage of prednisone (29) , which formed the basis of our weight-based criterion of ,0.2 mg/kg/day for remission in this pediatric cohort. Inactive disease was defined as an absence of disease activity (PVAS of 0), regardless of corticosteroid dosage. Improvement was defined as a decrease in the PVAS score by at least 50% postinduction (at 4-6 months after diagnosis) or at 12 months after diagnosis as compared to the time of diagnosis. This level of response is consistent with the definition of a clinically important improvement according to the EULAR recommendations (29) . A decrease in the PVAS of 70% or more was also studied as a measure of improvement.
Relapse was defined as recurrence or new onset of disease activity (an increase in the PVAS of $1, from 0) attributable to active inflammation. Major relapse was defined as the recurrence or new onset of potentially organ-or lifethreatening disease activity requiring an escalation in treatment, in addition to treatment with corticosteroids. Other relapses were considered minor.
In adult vasculitis, damage is scored according to the VDI, which is a validated tool for assessing damage from disease, treatment, or concurrent conditions (28) . Damage is considered irreversible and must be present for at least 3 months to be counted as an item in the VDI. There is no validated tool to assess disease damage in children with vasculitis. Therefore, in order to apply the VDI to our pediatric cohort of patients, we made the following modifications. 1) Hypertension in the adult VDI is defined as a diastolic blood pressure (BP) of $95 mm Hg or requiring treatment with antihypertensive agents; this was modified to a diastolic BP of .95th percentile for height and age or requiring treatment with antihypertensive agents. 2) Proteinuria in the adult VDI is defined as a level of $0.5 gm/24 hours; this was modified to a level of .0.3 gm/24 hours in order to be consistent with how proteinuria data are collected in this registry. The PRES Vasculitis Working Group and Childhood Arthritis & Rheumatology Research Alliance are currently working toward validating a formal pediatric modification of the VDI (31) . The modifications that were made to the VDI for this study align with the proposed changes by the PRES Vasculitis Working Group. Further considerations by the Working Group include the addition of other pediatric-specific items, such as growth delay, delayed puberty, and new-onset obesity. These items were also collected in the registry but not scored. In the present study, a PVDI score of 0 indicated no damage, while a score of 1 indicated the presence of 1 damage item (of a total of 64 potential damage items on the PVDI). A copy of the modified pediatric version of the VDI used for this study is provided in Supplementary Figure 1 
RESULTS
Characteristics of the patients. In total, 107 patients were eligible for inclusion in the study. The diagnosis in 2 patients was not classifiable as AAV according to the defined classification criteria, and therefore these 2 patients were excluded. Of the remaining 105 children, 81% were classified as having GPA, 13% as having MPA, and 6% as having EGPA. Among the 105 patients, 68% were female and 50% were white. Fifty percent of the patients did not have complete data on ethnicity or the ethnicity was unknown. The distribution of the ethnic groups is shown in Clinical presentation and laboratory test results. The majority of patients had pulmonary disease (80%) and/or renal disease (78%). Sixty-four patients (61%) had both pulmonary and renal disease. One-third of the patient cohort had alveolar hemorrhage or massive hemoptysis at presentation, and 10% were in respiratory failure. Seventeen patients (16%) were in renal failure requiring dialysis, and 5 patients (5%) had end-stage renal disease. Other systems involved in a majority of patients were ear, nose, and throat (ENT) (56%) and musculoskeletal (53%). Additional baseline clinical features are shown in Table 1 .
Of the 105 patients, 99 underwent immunofluorescence testing for ANCAs. Among these patients, 54% were positive for cytoplasmic ANCAs (cANCAs) (94% with proteinase 3 [PR3] specificity, 2% with myeloperoxidase [MPO] specificity, 4% with negative specificity), 32% were positive for perinuclear ANCAs (pANCAs) (91% with MPO specificity, 9% with PR3 specificity), 3% were mixed positive for both cANCAs and pANCAs, and 11% were negative for ANCAs. The 6 patients who did not undergo immunofluorescence testing had antigen specificity testing, which showed that 4 of the patients were PR3 positive and 2 were MPO positive.
Ninety-one patients (87%) had tissue biopsies performed as part of their diagnostic evaluation, of whom 61 patients (58%) had renal biopsies, 20 patients (19%) had skin biopsies, and 9 patients (9%) had paranasal sinus biopsies. Other biopsy sites included the gastrointestinal tract (8% of patients), upper airways (6% of patients), orbital masses (3% of patients), and other sites (7% of patients).
Treatment. For remission induction, cyclophosphamide (CYC) was used in 74 patients (70%), methotrexate (MTX) in 17 patients (16%), and rituximab (RTX) in 14 patients (13%). Four patients received both CYC and RTX. All patients who received RTX were diagnosed after 2010. RTX use did not appear to be center-specific, as it was used at 9 different sites; however, all sites were either in Canada or the US. Azathioprine (AZA) was used as the primary remissioninduction agent in 2 patients, and mycophenolate mofetil (MMF) was used in 1 patient. One patient received corticosteroid alone for remission induction, without any other primary immunosuppressant treatment. Plasmapheresis was used in conjunction with CYC and/or RTX in 25 patients (24%). Of these 25 patients who received plasmapheresis, 24 (96%) had renal disease and 21 (84%) had both pulmonary and renal disease. All patients received oral corticosteroids as part of their remission-induction treatment. Seventy-four patients (70%) were also treated with intravenous pulses of highdose methylprednisolone at the time of diagnosis. The dose and number of pulses used were highly variable, ranging from 10 mg/kg/dose to 30 mg/kg/dose and 1-12 pulses. Primary treatments used for remission induction are shown in Figure 1 . Treatments for remission maintenance were AZA in 45 patients (43%), MTX in 24 patients (23%), MMF in 14 patients (13%), CYC in 10 patients (9%), and RTX in 10 patients (9%) (Figure 2 ). At 12 months after diagnosis, 75 patients were either no longer receiving corticosteroids (32 patients [30%]) or were receiving a low dosage of corticosteroids (,0.2 mg/kg/day; 43 patients [41%]).
Outcomes. Remission. Forty-four patients (42%) achieved remission at 12 months (PVAS of 0, corticosteroid dosage ,0.2 mg/kg/day). Twenty-one (48%) of these 44 patients who achieved remission had discontinued their corticosteroid treatment by 12 months. All but 3 patients remained on maintenance treatment at 12 months (18 receiving AZA, 9 receiving MTX, 6 receiving RTX, 5 receiving MMF, and 3 receiving CYC).
Inactive disease. Fifty-one (49%) of the 105 patients had inactive disease (PVAS of 0) at postinduction (4-6 months after diagnosis), and 64 patients (61%) had inactive disease at 12 months (of whom 44 were described as being in remission, in that they were receiving a minimal dosage of corticosteroids or had discontinued corticosteroids by 12 months, whereas the remaining 20 patients had inactive disease at 12 months while continuing to receive a higher dosage of corticosteroids). Thirty-nine of the patients who had inactive disease postinduction continued to have inactive disease at 12 months.
Improvement postinduction. The majority of patients improved even if they did not achieve inactive disease by the postinduction visit. An improvement in the PVAS of at least 50% from the time of diagnosis to postinduction was seen in 92% of patients. An improvement in the PVAS of at least 70% was seen in 85% of patients. Four patients had no improvement or a worse PVAS during the postinduction time period.
Improvement at 12 months. An improvement in the PVAS of at least 50% from the time of diagnosis to 12 months was seen in 93% of patients, and an improvement of at least 70% was seen in 90% of patients. One Relapses. Relapses occurred in 12 (24%) of 51 patients after inactive disease had been achieved at the postinduction visit. All relapses were considered minor. Twenty-two (21%) of 105 patients had a worsening of the PVAS between the postinduction visit and the 12-month visit (PVAS worsened by 1 or more points, regardless of whether inactive disease [PVAS of 0] had been achieved at the postinduction visit).
Damage. Completed PVDI scores for damage were available for 104 patients. The median PVDI score at 12 months was 1 (range 0-6). Sixty-six (63%) of the 104 patients had $1 damage item scored as present at 12 months, 35 (34%) had $2 damage items scored as present, and 19 (18%) had $3 damage items scored as present. The distribution of PVDI scores is shown in Figure 3 , and the specific items scored across the various organ systems are shown in Table 2 .
One-third of the 104 patients had evidence of renal damage. The most frequent renal damage items scored as present were proteinuria (20%), an estimated/ measured glomerular filtration rate of #50% of normal (18%), and end-stage renal disease (12%). Two patients had received renal transplants. ENT damage was seen in 20% of patients, and pulmonary damage was seen in 15% of patients. Investigators were given the opportunity to enter other items that they believed would represent damage but were not included in the scoring form. Items that were entered more than once included chronic cough (3 patients), new-onset obesity (3 patients), and significant striae (5 patients).
Hospitalizations and deaths. Following the time of diagnosis, 43 patients reported a hospitalization during the follow-up (total of 80 hospitalizations). Hospitalizations for routine treatments were not included.
Almost one-half (46%) of the hospitalizations were in relation to disease flares, 16% were attributable to infection, and 5% were because of treatment-or medication-related adverse effects. Twelve hospitalizations (15%) were for other disease-related reasons, such as a renal biopsy or other tissue biopsy (beyond the time of diagnosis), investigational procedures such as endoscopies, or, in 1 patient, 3 admissions for physical rehabilitation. Fourteen hospitalizations (18%) were for reasons unrelated to the underlying disease or treatments, according to the site investigator. No deaths occurred.
Exploration of associations with remission at 12 months. We conducted an exploratory univariate analysis of a few selected baseline features to determine whether these features showed an association with remission at 12 months. Based on observations from The median age of patients who achieved remission was 14 years, compared to 13 years for patients who did not achieve remission (P 5 0.04). At 12 months, 55% of the male patients compared to 34% of the female patients achieved remission (P 5 0.06). Treatment was dichotomized into 2 groups, aggressive versus moderate. Aggressive treatment was defined as remission-induction medications that included CYC and/ or RTX, with or without plasmapheresis. Moderate treatment was defined as remission-induction medications that included MTX, AZA, or MMF. The 1 patient who received only corticosteroids for induction treatment was excluded from the treatment analysis. Rates of remission at 12 months postdiagnosis were similar between patients who received aggressive treatment and those who received moderate treatment (43% who received aggressive treatment achieved remission versus 30% who received moderate treatment; P 5 0.32). The median baseline PVAS for the patients who received aggressive treatment was 20, compared to a median baseline PVAS of 14 for the patients who received moderate treatment (P 5 0.0001).
There was minimal difference in the baseline PVAS score between patients who achieved remission at 12 months and those who did not achieve remission at 12 months (median baseline PVAS of 21 in the remission group versus 19 in the nonremission group; P 5 0.18). Similarly, ANCA subtype was not associated with remission, in that 42% of cANCA/PR3-positive patients achieved remission at 12 months compared to 38% of pANCA/MPO-positive patients (P 5 0.83).
DISCUSSION
This multicenter international study assessed the early disease course and outcomes in 105 patients with childhood-onset AAV. This is the largest cohort study to date to report pediatric outcomes in this group of diseases. Despite numerous adult-based studies and clinical trials reporting short-and long-term outcomes in AAV, our knowledge of pediatric-specific outcomes remains limited. Until now, the 2 largest pediatric studies in which outcomes have been described have included respective total sample sizes of 66 patients and 35 patients with AAV (20, 35) .
In our study, the majority of children had GPA. The median age at diagnosis (13.8 years) and predominance of female patients are consistent with the findings in other pediatric AAV studies (20, 35) . The high rates of renal disease (78%) and pulmonary disease (80%) at presentation are also consistent with those reported previously; however, children in our study had lower rates of ENT disease, at 56%, as compared to the reported rates of 70-90% in other recent studies (11, 20, 35, 36) . Treatment strategies were also consistent with those in previous studies, with the majority of patients receiving CYC in conjunction with corticosteroids for remission induction and then switching to AZA or MTX for remission maintenance (20, 35) . Disease activity, as measured using the PVAS, was not easily comparable to that in other studies, as it has only been reported in 1 previous study, the French Vasculitis Study Group cohort, in which the median PVAS was 9.5 for MPA, 12 for GPA, and 14.5 for EGPA (35) . The median baseline PVAS in our patients was higher, at a median of 19. The use of plasmapheresis in 50% of the patients may be an indicator of severe disease; however, it may also be a reflection of more recent practices or jurisdiction-based capacity or preferences.
A significant proportion of patients were not in remission at 12 months. The 12-month remission rate of 42% in our cohort was significantly lower than the remission rates reported by Sacri et al in their cohort (20) , which were 73% at postinduction and 90% for the overall remission rate (including secondary remissions after a median time of 6.7 months). In that study cohort, remission was assessed after remission-induction therapy had been initiated, but the criteria for remission did not need to be met within a specified time frame. Remission in the study by Sacri et al was defined as a Birmingham Vasculitis Activity Score (BVAS) of 0 or a BVAS for Wegener's Granulomatosis of 0 and corticosteroid dosage of #7.5 mg once daily (regardless of weight) (20) , which was similar to the criteria used in this study. Differences in remission rates between our study and the study by Sacri et al might be explained by several factors. 1) The patient characteristics were different, in that there were more patients with MPA in the French cohort and fewer patients with pulmonary disease. 2) Disease activity scoring was applied retrospectively in the French cohort, compared to use of an automated online calculator in conjunction with a clinic visit for the majority of patients in the PedVas cohort.
3) The timing of assessments was different; in our study, inactive disease was assessed at postinduction (specifically, 4-6 months after diagnosis), and remission was assessed at the 12-month visit. 4) The proportion of patients receiving treatments for remission induction in the French cohort were similar to those in our study (in the French cohort, 66% received CYC, 14% received RTX, and 17% received plasmapheresis). However, direct comparisons between the cohorts with regard to baseline disease activity, specifics of treatment regimens, and the basis behind treatment decisions could not be made.
Reported remission rates in several adult clinical trials in AAV have also shown variability, ranging between 53% and 93% (37) (38) (39) . The lower reported remission rates in some trials assessing adult patients have been attributed to several potential factors, including stricter corticosteroid-weaning protocols (for example, complete weaning by 6 months versus weaning by 12 months), stricter definitions of remission (BVAS of 0 versus BVAS of ,2), and longer duration of disease inactivity to define remission (3 months of inactive disease versus no minimum duration of inactive disease). For our study, the definition of remission required use of a minimum corticosteroid dosage at 12 months, and there was no minimum duration of inactive disease required; however, our criterion for disease activity was strict (PVAS of 0). These definitions were selected on the basis of recommendations for reporting outcomes in adult patients in clinical trials (29) , which were introduced in an attempt to reduce heterogeneity in outcomes reporting. It is acknowledged that the strict inclusion and exclusion criteria of clinical trials, in addition to the highly systematic approach to disease assessment, medication administration, and weaning, are not directly comparable to those in observational cohorts.
Selection of patients in clinical trials and strict protocols may allow for easier attainment of remission criteria at certain time points and may also result in selection of patients who are more likely to respond to treatment. Our registry included all patients with AAV regardless of baseline disease severity, disease activity, organ involvement, or specific treatments, all of which would be important factors in determining the chance of remission. In addition, the treating physician's protocol of continuing treatment with prednisone at a dosage of either .0.2 mg/kg/day or ,0.2 mg/kg/day might represent the physician's individual practice approach, rather than a patient-specific requirement to maintain control of inflammation. The remission rates reported in this study may be a better reflection of the remission rates seen in clinical practice as compared to what is reported from clinical trials.
Despite a significant proportion of patients not achieving inactive disease postinduction or not achieving remission at 12 months, the majority of patients met the definition of treatment response, with 92% of patients experiencing an improvement of at least 50% in the PVAS at postinduction. This is similar to the high rate of treatment response reported in the study by Sacri et al (20) . Relapses occurred in 24% of patients who achieved inactive disease at postinduction. This rate is lower than the reported rates of 40-80% in other pediatric studies, but our duration of follow-up was only 1 year, compared to a median follow-up of 2-8 years in other studies (20, 35, 40) . Longer-term follow-up data are needed to examine the relapse rates with current treatment regimens.
More than one-half of the patient cohort (63%) had evidence of damage by 12 months. A study by Iudici et al also assessed damage in a cohort of children with systemic necrotizing vasulitides (35) . They used the VDI to score damage and reported a median VDI score of 1 at last follow-up (median follow-up time 96 months), which is the same as the median PVDI score in our cohort at 12 months after diagnosis. The percentage of patients who had evidence of damage was not reported in the study by Iudici et al, and therefore it is difficult to make further comparisons. Robson and colleagues summarized the rates of damage in adult patients with AAV from 6 European Vasculitis Study Group studies, and found a similarly high rate of damage (87%) at 12 months (4). As in other studies of adult patients, the most frequently scored damage items in the study by Robson et al were renal items such as proteinuria and reduced glomerular filtration rate, followed by ENT items (4) . The fact that so many children already have evidence of renal damage within 12 months of diagnosis is concerning, considering that adults are more likely than children to have underlying preexisting renal disease, whereas we speculate that children might have some degree of renal reserve.
In our exploratory analyses, no significant associations with remission were found with regard to sex, age, ANCA status, remission-induction treatment, and the PVAS at baseline. Previous studies in adults have suggested that female sex, older age, less aggressive treatment, and PR3-ANCA status are associated with treatment resistance, reduced chance of remission, or higher relapse rates (8, 17, 33, 34) . Higher disease activity, as measured by the BVAS, has been associated with a higher chance of remission (independent of treatment) but poorer survival in adults with AAV (34, 41) . We recognize that disease activity, as measured by the PVAS, and treatment are likely to be related; however, due to limited patient numbers, we did not have the power to assess the effect of treatment as a modifier, nor were we able to incorporate the effects of remissionmaintenance treatments. The purpose of this analysis was to test for simple associations of baseline factors previously reported to be associated with outcome in adults. It is possible that the factors associated with remission in adults are not the same as those in pediatric patients; however, it is also possible that the sample size limited our power to detect associations. The size of the sample in the current study limited our analysis to remission as the primary outcome measure; however, predictive factors for other outcomes, such as relapse, damage, and survival, are also of interest, especially over the longer term. Increased numbers of patients will enable analyses with multiple variables and outcomes that will likely be more informative.
Our study had the following limitations. Formal training in scoring the PVAS was not required of site investigators; however, a comprehensive manual and an instructional PVAS video were provided to each site. The database was designed specifically to collect the clinical data required to calculate the PVAS; however, it is possible that items were incorrectly entered or missing. Patient data were collected at prespecified time points (time of diagnosis, postinduction, and 12 months), which meant that we were unable to capture precisely what happened between visits. For example, if a patient achieved remission after the postinduction visit but had a minor relapse prior to the 12-month visit (resulting in a PVAS of .0), then we would not have captured the remission or the relapse in such a patient. However, these instances are likely to be few, because investigators were asked at each visit whether the patient had experienced a relapse since the last visit, and all such instances were reviewed. Nevertheless, subtle relapses, according to our definition, may not necessarily have been captured, especially if the investigator did not routinely calculate the PVAS between study visits.
We used a modified version of the VDI to assess damage in this cohort, because there is currently no validated pediatric-specific VDI. It is not known whether scoring damage in this way is meaningful in the pediatric population, and further studies, including validation studies, are needed to determine the extent to which this tool will effectively capture damage accrual in pediatric vasculitis patients.
Finally, for the 22 patients in the cohort who were diagnosed before March 2007, data were entered retrospectively and may have been subject to recall bias or missing data. The reliability and utility of retrospectively entered PVAS and PVDI scores have not been studied. This is the largest study to date to report outcomes in pediatric AAV. Although we found that a significant proportion of patients did not achieve remission, the majority of patients responded to treatment. Unfortunately, more than one-half of the patient cohort experienced damage early in the disease course. Ongoing collection of clinical and biologic data through the PedVas initiative and other international collaborations will allow for further exploration and comparison of early, as well as longer-term, outcomes. A study of outcome predictors is currently underway.
